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Summary
Thiamine metabolism genes are regulated in numer-
ous bacteria by a riboswitch class that binds the coen-
zyme thiamine pyrophosphate (TPP). We demonstrate
that the antimicrobial action of the thiamine analog
pyrithiamine (PT) is mediated by interaction with TPP
riboswitches in bacteria and fungi. For example, pyri-
thiamine pyrophosphate (PTPP) binds the TPP ribo-
switch controlling the tenA operon inBacillus subtilis.
Expression of a TPP riboswitch-regulated reporter
gene is reduced in transgenic B. subtilis or Escheri-
chia coli when grown in the presence of thiamine or
PT, while mutant riboswitches in these organisms
are unresponsive to these ligands. Bacteria selected
for PT resistance bear specific mutations that disrupt
ligand binding to TPP riboswitches and derepress cer-
tain TPP metabolic genes. Our findings demonstrate
that riboswitches can serve as antimicrobial drug tar-
gets and expand our understanding of thiamine me-
tabolism in bacteria.
Introduction
Riboswitches are conserved RNA elements that form re-
ceptors for specific small molecules and regulate gene
expression in response to ligand binding [1–3]. For all
classes of riboswitches studied so far, ligand binding
by these RNAs can occur in the complete absence of
protein. Riboswitch-regulated genes are involved in nu-
merous bacterial biosynthetic pathways, and more than
2% of the genes in certain bacteria are riboswitch regu-
lated [4]. Riboswitches typically exhibit remarkable
specificity, 100- to 1000-fold or more, for their cognate
ligands versus highly related compounds [5–7]. This
high level of molecular discrimination allows these
RNA genetic switches to selectively control gene ex-
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lated compounds in cells.
A class of riboswitches that binds thiamine pyrophos-
phate (TPP) regulates genes that code for protein prod-
ucts involved in the biosynthesis and transport of thia-
mine in numerous bacteria. While most bacteria can
synthesize thiamine de novo, all animals and many fungi
require supplemental thiamine or its immediate precur-
sors [8, 9]. Intracellular thiamine is then phosphorylated
to TPP and participates as a coenzyme for enzymes
that cleave carbon-carbon bonds adjacent to a carbonyl
group for processes including glycolysis, the citric acid
cycle, and the pentose phosphate pathway. Maintaining
adequate levels of TPP and sufficient activity of TPP-
utilizing enzymes is essential to all known cellular life
forms.
Decades ago, when vitamins were first being identi-
fied and structurally characterized, pyrithiamine (PT)
was designed to be an isosteric pyridine analog of thia-
mine and synthesized for the study of thiamine metabo-
lism (Figure 1A) [8–10]. PT was quickly shown to be toxic
in small amounts to fungi and bacteria that require sup-
plemental thiamine [11, 12] and to induce thiamine defi-
ciency in mice [13] and pigeons [14]. It is now known that
PT, like thiamine, is phosphorylated in cells to pyrithi-
amine pyrophosphate (PTPP), most likely by thiamine
pyrophosphorylase (TPK) [8, 15, 16]. In eukaryotes, PT
inhibits the conversion of dietary thiamine to TPP and
PTPP inhibits enzymes that use TPP as a coenzyme
[15, 17–20]. In mammals, PT crosses the blood-brain
barrier, inhibits TPK, reduces thiamine transport into
the brain, and leads to an overall reduction in total thia-
mine levels [21]. These features are routinely exploited
to induce thiamine deficiency in animal models to study
thiamine deficiency disorders (e.g., [22–24]). Thus, PT
and PTPP compete for thiamine and TPP binding sites
on proteins. Bacteria and fungi that synthesize TPP de
novo might be expected to overcome the effects of PT
by upregulating thiamine production. However, these
organisms are also susceptible to the effects of PT,
and for several decades, the full spectrum of toxic ef-
fects of this thiamine analog on bacteria and fungi has
remained unknown [25, 26].
Intriguingly, PT had previously been shown to alter the
regulation of thiamine biosynthesis enzymes in bacteria
and fungi. In E. coli, for example, PT-resistant mutants
show derepression of enzyme activities leading to bio-
synthesis of thiamine and TPP [26]. In the filamentous
fungus Aspergillus oryzae, transcripts of a putative thia-
mine precursor biosynthetic gene, thiA, are reduced in
number in cells grown with either thiamine or PT. A resis-
tant mutant has been obtained that shows derepression
of the thiA gene with both compounds [25]. Interestingly,
this resistance is conferred by a point mutation in the
50 untranslated region (50-UTR) of the thiA transcript,
while no changes occur in the protein coding region. The
50-UTR is predicted to contain two introns; deletions in
the 50-UTR alter thiamine-mediated regulation and also
cause aberrant splicing [27]. This suggested a role for
PT in altering proper processing of the thiA 50-UTR and
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(A) Chemical structures of thiamine, TPP, PT,
and PTPP. PT differs as shown with the re-
placement of the thiazole (Thz) moiety with
a pyridine ring (boxed). The hydroxymethyl-
pyrimidine (HMP) moiety (shaded) is un-
changed from thiamine in both PT and PTPP.
(B) The biosynthesis of HMP-PP and Thz-P
in B. subtilis and E. coli. Genes regulated
by TPP riboswitches in B. subtilis are shown
to the left of the reaction pathway and in
E. coli to the right of each pathway and
shaded yellow. See Table S1 for additional
information. Black type: genes regulated by
TPP riboswitches; gray type: genes not reg-
ulated by TPP riboswitches. Colored bars
denote transcriptional units. AIR, 5-amino-
imidazole ribonucleotide; HMP-P, hydroxy-
methylpyrimidine monophosphate; HMP-PP,
hydroxymethylpyrimidine pyrophosphate;
Thz-P, thiazole monophosphate. In E. coli,
the activity of ThiC requires at least one
other cellular factor [36], so it is possible that
B. subtilis requires an additional factor as
well, denoted with question marks.
(C) The biosynthesis of TPP from HMP-PP
and Thz-P. Notations are as in (B). TP, thia-
mine monophosphate. Box: complete list of
genes controlled by TPP riboswitches in
B. subtilis (left) and E. coli (right, shaded
yellow).led us to investigate the possibility that PT interacts with
riboswitches in the 50-UTRs of both bacteria and fungi.
A precedent for interaction between an antimicrobial
compound and a riboswitch exists. Previously, we re-
ported that a toxic analog of lysine, S-(2-aminoethyl)-
L-cysteine (AEC), binds to the lysine riboswitch with
only a 30-fold reduction in affinity in vitro compared to
lysine [28]. Elevated AEC concentrations regulate ex-
pression of a reporter gene that carries a lysine ribo-
switch. Point mutations of conserved nucleotides in
the lysine riboswitch confer resistance to AEC toxicity
and also abolish regulation of reporter gene expression.
In light of these results, we examined the interaction of
TPP riboswitches from fungi and bacteria with both PT
and PTPP. As a result of the observed pattern of ribo-
switch binding and gene regulation induced by PT and
its derivatives, we conclude that binding of PTPP to
TPP riboswitches contributes to the antimicrobial effect
of this compound. We also provide evidence that spon-
taneous bacterial resistance to PT emerges through mu-
tations to a TPP riboswitch controlling key thiamine met-
abolic genes. These findings have implications both for
practical development of new antibacterial drugs and
for the basic understanding of coenzyme biosynthesis
and metabolism.
Results and Discussion
TPP Riboswitches Regulate Bacterial Thiamine
Biosynthesis and Transport
Both E. coli and B. subtilis can either synthesize TPP
or import and phosphorylate thiamine, and both are
normally susceptible to the toxic effects of PT (seeFigure S1 in the Supplemental Data available with this
article online). There are three operons in E. coli that
were determined using bioinformatics to each carry
a conserved TPP riboswitch motif in the 50-UTR, as
listed in the RNA family database Rfam [29, 30]. Expres-
sion of these genes is known to be attenuated in re-
sponse to TPP in certain bacteria [31]. We found that
two of these RNAs exhibit protein-free binding of TPP
in vitro and that these elements confer genetic regula-
tion to reporter genes in vivo [6]. In B. subtilis, there
are five transcriptional units (two operons and three sin-
gle genes) that carry TPP riboswitch motifs [32]. These
are all predicted to form intrinsic transcription termina-
tors in the presence of TPP and to repress expression
of thiamine biosynthetic and transport genes. One op-
eron has been confirmed to undergo transcriptional at-
tenuation with TPP [33]. Additional information on these
genes and their functions are listed in Table S1.
The TPP riboswitch motifs of E. coli and B. subtilis are
located upstream of open reading frames (ORFs) for nu-
merous thiamine metabolism proteins. Thiamine is syn-
thesized by an enzymatic condensation of two precur-
sors that provide the pyrimidine moiety (HMP) and
thiazole moiety (Thz) of thiamine [34, 35]. The precursors
are either synthesized de novo, transported, or salvaged
and phosphorylated to HMP-PP and Thz-P prior to the
condensation. Nearly all of the genes needed for HMP-
PP and Thz-P synthesis are located downstream of TPP
riboswitch motifs (Figure 1B). The details of HMP-PP
synthesis are not completely understood [36], but
TPP riboswitches are associated with genes that are crit-
ical for HMP-PP synthesis and phosphorylation. Thz-P
synthesis has been completely reconstituted with both
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involves several steps and numerous gene products
[37, 38]. The gene products of nifS, yfhO (also known
as iscS), and dxs are needed both for thiamine metabo-
lism and for other pathways, so it is not surprising that
they are independent of TPP riboswitch control. Some
differences in thiamine synthesis exist between E. coli
and B. subtilis and are detailed in Figure 1. For example,
phosphorylation of salvaged Thz is riboswitch associ-
ated in B. subtilis but not in E. coli.
The expression of proteins involved in the final syn-
thetic steps of TPP is not extensively regulated by TPP
riboswitches. The precursors HMP-PP and Thz-P are
condensed to thiamine monophosphate (TP) by ThiE,
with the pyrophosphate of HMP-PP serving as the leav-
ing group for the reaction and the phosphate of Thz-P
being retained in TP (Figure 1C). The thiE gene is asso-
ciated with a TPP riboswitch in E. coli but not B. subtilis.
Both newly synthesized TP and salvaged thiamine must
be phosphorylated to TPP. None of the kinases for these
phosphorylations are associated with TPP riboswitches.
Not shown in Figure 1 are pathways for transport of
thiamine compounds. Although thiamine transport has
not been fully characterized in these organisms, some
details are known. In E. coli, the riboswitch-regulated
operon tpbA-yabK-yabJ encodes proteins that trans-
port thiamine, TP, and TPP [35]. In B. subtilis, the
ykoF-C operon and yuaJ putatively code for transport
proteins for HMP and thiamine, respectively [39]. The
levels of these proteins also appear to be controlled by
TPP riboswitches. PT is known to be imported into yeast
cells via thiamine transport proteins [18]. Therefore, PT
could enter bacterial cells by analogous transporters in
addition, perhaps, to passive diffusion.
The presence of TPP riboswitch motifs in the mRNAs
of thiamine metabolic genes suggests a feedback loop
is operating whereby TPP levels control the import of
thiamine and the synthesis of thiamine precursors.
Free TPP in the cell should bind simultaneously to all
TPP riboswitches in actively transcribed mRNAs in
these pathways and globally influence expression of
these genes. If a thiamine analog such as PT could
bind these riboswitches in vivo, a similar widespread re-
duction in expression of thiamine metabolic genes
should occur. To begin our assessment of whether PT
toxicity could be due to interactions with TPP ribo-
switches, we first investigated the binding behavior of
TPP riboswitches in vitro with thiamine, PT, and their
pyrophosphorylated derivatives.
Bacterial TPP Riboswitches Bind PTPP
The majority of known thiamine biosynthesis genes in
B. subtilis are contained in the tenA-tenI-goxB-thiS-
thiG-thiF-yjbV operon (called tenA hereafter). To com-
plement the published data that TPP attenuates tran-
scription of this operon in vitro [33], we tested direct
binding of TPP to the 50-UTR of the tenA operon (Fig-
ure 2). The construct employed for these tests included
both the aptamer for binding TPP (Figure 2B) and the ex-
pression platform for transducing ligand binding into
gene expression regulation [40]. The expression plat-
form in this case controls the formation of an intrinsic
terminator of transcription (Figure 2A). As for many ribo-
switch classes, ligand binding is permitted when thebase-paired structure termed P1 is formed. The intrinsic
terminator then forms and transcription of the down-
stream genes is repressed. If levels of TPP are low and
no ligand is bound to the riboswitch, the nucleotides in
P1 are free to form an antiterminator and transcription
of several thiamine biosynthetic genes in the operon
proceeds.
An RNA corresponding to nucleotides 2185 to 223
relative to the translation start site of tenA was tran-
scribed and submitted to an in-line probing assay where
changes in RNA structure due to ligand binding can be
determined by changes in the levels of spontaneous
RNA degradation [41–43]. TPP was incubated with the
RNA in a range of concentrations from 1 nM to 100 mM.
The results confirmed the tenA RNA is a functional TPP
aptamer (Figure 2C). As the concentration of TPP was in-
creased, significant changes in spontaneous cleavage
occurred at nucleotides such as A36, A61, and A63.
The apparent KD of the riboswitch aptamer for TPP was
determined by in-line probing as described previously
[6] and found to be 50 nM (Table 1). To determine
whether TPP riboswitches are targets of pyrithiamine,
the PT-resistant strain 1A481 was obtained from the
Bacillus Genetic Stock Center (The Ohio State Univer-
sity) and sequenced at each of the five B. subtilis TPP
riboswitches. A single nucleotide change from G to A
in the tenA 50-UTR was found (Figure 2A). In-line probing
of the mutant riboswitch revealed much less pro-
nounced changes in the pattern of spontaneous degra-
dation including at sites A36, A61, and A63 (Figure 2D)
with a reduction in affinity by 36-fold to a KD of 1.8 mM
(Table 1).
High (10 mM) concentrations of either thiamine or PT
showed little evidence of binding to the wild-type ribo-
switch (Figure 2C). The affinities for either ligand were
found to be 100- to 1000-fold poorer than for TPP
(Table 1). This loss in affinity for the nonphosphorylated
form is in good agreement with previous results for thia-
mine and TPP with E. coli riboswitches [6]. To mimic the
natural ligand more closely in the in-line probing assay,
PTPP was synthesized from PT and phosphoric acid
(see Experimental Procedures) and tested for binding
to the wild-type and mutant riboswitch constructs. The
wild-type tenA riboswitch shows a TPP-like pattern of
spontaneous RNA degradation in the presence of a mod-
est 100 nM concentration of PTPP (Figure 2C). The mu-
tant tenA riboswitch fails to show TPP-like structural
modulation even with significantly higher (1 mM) PTPP.
The affinities for binding PTPP by the wild-type tenA or
the mutant riboswitch constructs are nearly identical to
those for binding TPP (Table 1). The difference in affinity
between PT and PTPP matches the difference in affinity
between thiamine and TPP, suggesting that these ana-
logs might be bound by TPP riboswitches using the same
molecular contacts. Therefore, PT in the form of PTPP is
very likely to interact with TPP riboswitches in vivo.
The mutant riboswitch from the PT-resistantB. subtilis
strain has an w40-fold reduced affinity for TPP and
a 10-fold reduced affinity for PTPP. The G to A mutation
at nucleotide 94 is a good candidate to confer PT resis-
tance by disrupting proper TPP aptamer formation in the
riboswitch. P1 is weakened by the mutation but the anti-
terminator is not expected to be adversely affected (see
Figure 2A legend). The same trend is also observed in
Chemistry & Biology
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(A) The B. subtilis tenA 50-UTR constructs used for in-line probing. Depicted are nucleotides2185 to223 (relative to the translation start) of the
wild-type 50-UTR. The resistant mutant sequence is derived from the PT-resistant strain 1A481 and bears the mutation shown. The sequence
50-GCGUAGGGAA AUGGAGCCAA ACCACUUUUC CUUGCGGG-30 from this mutant has a change in free energy on folding of 214.4 kcal/mol
as calculated on the mfold server [62, 63]. P1–P5 denote base-paired elements. G residues denoted with asterisks were added to aid in vitro
transcription.
(B) Consensus TPP riboswitch, reprinted with permission from the journal RNA. Red nucleotides are conserved in >90% of 100 bacterial and
archaeal TPP riboswitches. Circles denote nucleotides whose exact identity is not conserved. var., variable regions.
(C) In-line probing of the wild-type tenA riboswitch. RNA was incubated with concentrations of TPP ranging from 1 nM to 100 mM, or with PTPP
at 100 nM, thiamine (thi) at 10 mM, or PT at 10 mM. Markers were generated by partial digestion with RNase T1 to cleave after G residues (e.g.,
those labeled at left in figure) or with alkali, denoted OH2 NR and NL indicate no reaction and no ligand, respectively. Sites of significant ligand-
induced structural modulation are labeled A36, A61, and A63. The red arrowhead indicates the expected position of the mutation G94A shown
in (D).
(D) In-line probing of the mutant tenA riboswitch. RNA was incubated with ligands as in (C), except with PTPP raised to 1 mM. Other notations
are as in (C).TPP/PTPP binding with the thiC operon riboswitch from
E. coli (data not shown). The wild-type E. coli riboswitch
binds TPP and PTPP well but not thiamine or PT. The
PT-resistant E. coli strain PT-R1 had been created
many years ago [44] to investigate thiamine metabolism,
and the mutation that conferred PT resistance was map-
ped at that time to the thiC operon region. We obtained
the strain from the E. coli Genetic Stock Center (Yale
University), sequenced the 50-UTR of the thiC operon,
and found a deletion of the conserved G between P2and P3 (Figure 2B). As predicted due to the disruption
of the consensus aptamer, this mutant riboswitch
does not bind either TPP or PTPP well.
These results indicate that bacterial TPP riboswitches
bind PTPP well in vitro and that PT resistance is associ-
ated with reduced ligand binding by mutated TPP ribo-
switches in bacteria. We next investigated whether the
specificity of a eukaryote TPP riboswitch would be
similar to the bacterial examples by measuring PTPP
binding.
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There is a PT-resistant strain of A. oryzae that has been
developed and commercialized into a dominant select-
able marker for fungal transformations (TaKaRa Bio,
Shiga, Japan) [25, 45]. The TPP riboswitch is currently
the only riboswitch known in eukaryotes [46] and the
mutant fungal allele was found to have a single A to G
change in the 50-UTR with no changes at all in the protein
coding region (Figure 3A) [25]. The 50-UTR of A. oryzae
thiA was previously shown to contain a consensus
TPP riboswitch motif [46]. The sequence from 2233 to
261 relative to the translation start site of wild-type
thiA was tested by in-line probing to confirm it as a
TPP aptamer (Figure 3). Distinct changes in the pattern
of spontaneous RNA degradation occur in the A. oryzae
riboswitch at positions G141 and A123. The apparent KD
of this RNA for TPP is 56 nM (Table 1). PTPP is bound by
the riboswitch with a nearly identical KD of 50 nM. These
values are also in good agreement with the ligand affinity
of a TPP riboswitch from Arabidopsis thaliana [46].
The mutation in the PT-resistant allele occurs at a nu-
cleotide that is conserved in >90% of TPP riboswitches
examined from bacteria and eukaryotes [40, 46]. The af-
finity of the mutant riboswitch from the PT-resistant
A. oryzae strain is reduced by 71-fold for TPP and by
40-fold for PTPP. We also noted that the thiA TPP ribo-
switch carries what appeared to be an A insertion (Fig-
ure 3A, nonconsensus) relative to the consensus TPP ap-
tamer (Figure 2B). To test whether this difference alters
TPP binding, the construct without this A was prepared
and tested by in-line probing. Aptamers with and without
this A both bind TPP and PTPP well (Table 1), suggesting
that this nucleotide does not influence ligand binding.
These results show that TPP riboswitches from multi-
ple organisms and two domains of life bind PTPP ex-
tremely well in vitro and that PT resistance correlates
with mutations in TPP riboswitches among evolution-
arily diverse organisms. To show directly that PT influen-
ces gene expression via TPP riboswitches, we next in-
vestigated the expression of riboswitch-reporter gene
fusions in transgenic bacteria.
PT Inhibits Expression of Reporter Genes Driven
by TPP Riboswitches
Previously, we showed that extracellular thiamine re-
duces expression of a reporter gene under riboswitch
control in E. coli [6]. Similarly, it has also been shown
that extracellular PT reduces expression of chromo-
Table 1. Apparent KD Values of TPP Riboswitches
B. subtilis Wild Type Mutant
Loss of Affinity
(Mutant O Wild Type)
TPP 50 nM 1.8 mM 36
PTPP 160 nM 1.6 mM 10
Thiamine 50 mM nd nd
PT 6 mM nd nd
A. oryzae Wild Type Mutant
Loss of Affinity
(Mutant O Wild Type)
Consensus
Aptamer
TPP 56 nM 4 mM 71 20 nM
PTPP 50 nM 2 mM 40 56 nM
Values were determined in vitro by in-line probing of the constructs
detailed in Figures 2 and 3. nd, not determined.somal thiA in A. oryzae [25]. In this study, we used re-
porter gene constructs fused to the TPP riboswitch,
without any other chromosomal elements. We expected
that PT would enter cells, be pyrophosphorylated enzy-
matically to PTPP, bind the TPP riboswitch controlling
reporter gene expression with high affinity, and thereby
repress reporter gene expression. Specifically, ribo-
switch-reporter gene constructs were created by fusing
the appropriate 50-UTR sequence with a lacZ gene. In
B. subtilis strain 1A40 (PT-sensitive), cells grown in min-
imal medium produced a Miller value of 66.8 units (see
Experimental Procedures) for lacZ expression (Fig-
ure 4A). When either thiamine or PT was added to the
medium, the expression of lacZ dropped by more than
5-fold. The mutant TPP riboswitch from strain 1A481 ex-
hibits b-galactosidase activity similar to that of wild type
(94 Miller units in medium alone). However, adding either
thiamine or PT produced very little or no repression of
lacZ, showing that the mutant TPP riboswitch fails to
regulate genes, as expected.
As a control, the impact of PT toxicity on the reporter
assay was assessed by repeating the assay in a strain of
bacteria that is resistant to PT. The basal expression of
the reporter gene with the wild-type riboswitch is 44.5
Miller units. Because reporter gene expression is not
substantially repressed, compared to its expression in
the wild-type genetic background, TPP must not be
greatly overexpressed in this resistant strain during the
incubation time for the assay. All observed results follow
the same trend in this background as in the sensitive
strain (Figure 4B). Thus, the addition of PT is sufficient
to cause repression of genes controlled by TPP ribo-
switches. Furthermore, mutant riboswitches that cannot
bind TPP or PTPP in vitro do not exhibit regulation of re-
porter gene expression by thiamine or PT.
Reporter assays were also conducted in a wild-type
E. coli (lacZ2) strain transformed with either a wild-type
thiC TPP riboswitch-gene fusion or with lacZ fused to
a mutant riboswitch from the PT-R1 strain. The pattern
in gene expression is the same as that described for
B. subtilis (Figure 4C). Thus, multiple examples of bacte-
rial TPP riboswitches regulate genes in response to extra-
cellular PT as though thiamine were being added instead.
This indicates that PT enters cells and interacts with TPP
riboswitches broadly, most likely in the form of PTPP.
TPP Riboswitches Are Often Mutated
in PT-Resistant Bacteria
We hypothesize that a key mechanism of PT toxicity is
the binding of PTPP to TPP riboswitches, repression
of TPP transport and biosynthetic genes, and starvation
of the cell for TPP. In order to provide direct evidence of
this model, we sought to analyze additional PT-resistant
strains. PT-resistant bacteria are not commonly used
in research and the strains that yielded the mutant TPP
riboswitches used in these reporter gene assays were
the only such examples available in the B. subtilis and
E. coli stock centers. To study PT toxicity more generally,
we generated several additional PT-resistant strains.
PT-sensitive strains of both B. subtilis and E. coli were
exposed to PT in defined media without thiamine and
allowed to incubate until dense growth occurred. Surviv-
ing cells were passaged into fresh medium with and with-
out PT until cultures grew identically regardless of PT.
Chemistry & Biology
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(A) The A. oryzae thiA 50-UTR constructs
used for in-line probing. Depicted are nucleo-
tides 2233 to 261 of the wild-type 50-UTR.
The boxed G identifies the mutation carried
in the PT-resistant allele ptrA [25]; large dele-
tions that were previously reported to inter-
fere with regulation and expression are
shaded light gray or shaded and boxed.
The nonconsensus A residue is circled.
Stem P3 is longer than in bacteria, carries
occasional mismatches, and has no changes
in the mutant.
(B) In-line probing of the wild-type thiA ribo-
switch. RNA was incubated with concentra-
tions of TPP as in Figure 2C, with PTPP at
300 nM, thiamine (thi) at 1 mM, or PT at 1 mM.
Other notations are as in Figure 2.B. subtilis tenA or E. coli thiC TPP riboswitches were
then sequenced from individual colonies to check for
mutations in regulation of the major TPP biosynthetic
operons.
Surprisingly, all of the PT-resistant B. subtilis clones
acquired mutations in the tenA riboswitch (Figure 5A).
These are mostly point mutations that alter conserved
nucleotides in the TPP aptamer (Figure 5A, compare to
Figure 2B) but one clone carries an insertion in the ex-
pression platform also. The preponderance of tenA
riboswitch mutations in PT-resistantB. subtilis suggests
that this riboswitch is the primary cellular PT target.
Interestingly, the sequencing of the E. coli mutants
yielded a different pattern of mutations. Only 7 of the 23
clones carry mutations in the thiC riboswitch (Figure 5B).
The remaining 16 E. coli clones were then sequenced at
the other two TPP riboswitches. One carried a U insertion
in the conserved P2 stem of the thiM-thiD operon ribo-
switch, which is expected to greatly weaken this stem
and prevent TPP/PTPP binding (data not shown). Be-
cause the phosphorylation of HMP-P catalyzed by thiDis essential for thiamine biosynthesis, it is possible that
derepression of the gene maximizes conversion of
HMP-P to TP and confers PT resistance. Another clone
carries a G insertion in the nonconserved loop of P3 of
the riboswitch controlling the tbpA-yabK-yabJ operon,
which is not expected to impact ligand binding and is
therefore unlikely to be functionally relevant. Mutations
in the tbpA riboswitch that prevent PTPP binding and de-
repress these genes would be expected to increase tox-
icity in defined (thiamine-free) medium, as these thi/TP/
TPP transporters likely transport PT into the cell. Pre-
sumably, the remaining 14 clones from E. coli that do
not carry riboswitch mutations have gained resistance
by some other mechanism.
B. subtilis May Hydrolyze PT to Escape Toxicity
The functions of all of the E. coli genes regulated by TPP
riboswitches are known to be involved in thiamine bio-
synthesis and transport. Analogous genes are known
to be controlled by TPP riboswitches in B. subtilis as
well. However, a few B. subtilis genes without a knownFigure 4. Riboswitch Regulation of lacZ Expression in Response to PT
(A) b-galactosidase expression controlled by a TPP riboswitch in wild-type B. subtilis. Cells were incubated in defined media with no added
supplement (–), with 10 mM thiamine (thi), or with 10 mM PT (PT). B. subtilis has no endogenous b-galactosidase activity, and all expression is
due to the reporter gene. The riboswitch used to control the lacZ gene is indicated above each cluster of results: either PT-susceptible (wild-
type) or PT-resistant (mutant). The amount of repression of b-galactosidase activity measured in Miller units is shown boxed as the ratio with-
out supplement and with either thiamine or PT.
(B) Same assay as in (A) but in PT-resistant strain 1A481.
(C) Reporter assay with E. coli. The assay was performed as in (A) with an E. coli strain that is PT sensitive and lacZ2. The PT-resistant strain is
lacZ+ and so could not be used as a control for PT toxicity as in B. subtilis.
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PT Resistance
(A) All 23 of the B. subtilis clones bore muta-
tions in tenA TPP riboswitches and were dis-
tributed into three classes termed BNa1,
BNa2, and BNa3.
(B) In E. coli, seven clones acquired muta-
tions in thiC TPP riboswitches (class ETc1)
and one clone acquired a mutation in the
thiM riboswitch (class ETm1, not shown).
The expression platform of the E. coli ribo-
switch is a Shine-Dalgarno hiding mecha-
nism (shaded). The remaining 15 clones do
not have mutations in TPP riboswitches.role in thiamine metabolism (tenA, tenI, and ylmB) are
regulated by TPP riboswitches. TenA and TenI were
originally reported to be transcriptional enhancers
when overexpressed [47]. Bioinformatics has revealed,
though, that tenA is associated with thiamine metabo-
lism genes and TPP riboswitches in most bacteria [39].
We have already shown that although B. subtilis has
a complete TPP biosynthetic pathway that could be tar-
geted by PT at both the RNA and protein level, mutations
are always observed in the tenA riboswitch (which regu-
lates both tenA and tenI) in PT-resistant clones. Recent
structural and biochemical analysis of TenA fromB. sub-
tilis reveals it to be a type II thiaminase [48, 49]. Other
recent structures of archeal TenA homologs support dif-
ferent conclusions [50, 51], though these lack biochem-
ical supporting data and may not be relevant to eubac-
terial TenA. The physiological roles of either type I or
type II thiaminases are currently unknown [52–54]. How-
ever, the regulation of tenA expression by TPP ribo-
switches, the assignment to TenA of a function related
to thiamine metabolism, and the targeting of the tenA
riboswitch specifically by PT all support a role for TenA
in thiamine metabolism in B. subtilis.
We suggest a model that assigns a role for TenA both
in normal thiamine metabolism and PT resistance. All of
our PT-resistant B. subtilis clones are predicted to carry
tenA riboswitches with mutations that prevent binding
of either TPP or PTPP and therefore prevent repression
of the genes in the tenA operon. If so, then these strains
constitutively express a thiaminase despite, as we pro-
pose, being subjected to PT-induced thiamine starva-
tion. It is possible that TenA accepts PT as a substrate,
directly detoxifies it by hydrolysis, and contributes HMP
to the salvage pathway for thiamine biosynthesis (Fig-
ure 6). Type II thiaminases hydrolyze thiamine into
HMP and Thz but do not act on TPP [55]. Type I thiami-
nases accept a variety of nucleophiles and catalyze an
exchange with either thiamine or TPP that yields free
Thz (or Thz-PP) and an adduct of HMP. TenA was shown
to have an affinity for HMP [48], which is the common
moiety between thiamine and PT. The model type I
and type II thiaminases from Bacillus thiaminolyticus
(Paenibacillus thiaminolyticus) andBacillus aneurinolyti-
cus, respectively, have been reported to have activity
against a pyrimidinyl-pyridine compound (of which PT
is a type) [52]. Furthermore, the effects of PT were mea-
sured on fungal species, including two that cannot bio-
synthesize HMP and require HMP supplementation.These fungi grow if provided with subtoxic amounts of
PT, presumably by obtaining HMP from PT and con-
densing it with biosynthesized Thz-P [11]. This suggests
the presence of an enzyme that recovers HMP from PT in
these fungi.
In our model, HMP liberated from PT by TenA would
be phosphorylated to HMP-PP by YjbV, and could be
a source of HMP-PP despite continued repression of
thiC by PTPP binding to its riboswitch. Therefore, all of
the genes necessary to generate HMP-PP and Thz-P
are derepressed in a strain with a mutated tenA ribo-
switch. ThiE coupling will proceed normally. Any free
thiamine could be degraded by the elevated TenA con-
centration; however, the HMP and Thz moieties would
simply be rephosphorylated, recoupled to TP, and re-
phosphorylated to TPP. Degradation of TPP by TenA
would not occur because TenA does not act on TPP [48].
This model requires that type II thiaminases primarily
recognize thiamine via the HMP moiety rather than the
entire molecule. It has been suggested before that
HMP serves as a recognition site for a thiamine trans-
porter that also transports the thiamine analog ampro-
lium [56], and PT could therefore enjoy a similar level
of recognition by TenA. Furthermore, the role of TenA as
a thiaminase is consistent with a previous report that
B. subtilis TenA complements a thiC deletion in E. coli
[57]. The E. coli cells could compensate for an inability
to synthesize HMP via ThiC by increasing their salvage
of HMP via TenA from PT or other HMP-containing com-
pounds such as those produced by the activity of type I
thiaminases. Overall, this model provides one possible
explanation of the marked bias observed in the type
of mutations correlating with PT resistance between
B. subtilis and E. coli. It serves to explain this bias by
concentrating on the difference in the genes encoded
by the major TPP biosynthetic operons between these
two organisms, namely the tenA and tenI genes. How-
ever, there are certainly alternative explanations and fur-
ther testing of TenA function is needed to distinguish
among these possibilities.
As a result of this study on the interactions between
PT and TPP riboswitches, two new hypotheses emerge.
The first is that the physiological role of TenA is to hydro-
lyze HMP-containing compounds, such as those gener-
ated by type I thiaminases. The second is that TenA
directly detoxifies PT and that derepressing its synthe-
sis by mutation to its TPP riboswitch is an effective strat-
egy for resisting PT toxicity. The binding and reporter
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The effect of derepression of the tenA op-
eron on gene expression in PT-resistant mu-
tants is shown. Components of the path-
ways in gray type remain repressed. Thick
black arrows indicate derepression and thin
black arrows denote no riboswitch-mediated
change in expression. The putative detoxify-
ing role in PT resistance of TenA as a type II
thiaminase and pyrithiaminase is shown.expression data contained in this report validate TPP
riboswitches as antimicrobial drug targets. These results
indicate that both TPP and lysine riboswitches are tar-
gets of antimicrobial drugs. Both PT and AEC were first
synthesized several decades ago but the full impact of
their physiologic effects has remained unknown. The
demonstration now that both compounds interact with
riboswitches indicates that additional metabolite ana-
logs could be actively developed for riboswitch binding,
leading to antimicrobial effects.
Significance
In this report, we have demonstrated that PT exerts
toxic effects by interacting with TPP riboswitches. Re-
porter protein expression regulated by wild-type TPP
riboswitches is influenced both by extracellular thia-
mine and PT. Furthermore, bacterial and fungal popu-
lations can both acquire PT resistance by selecting
mutationswithin specific TPP riboswitches. In vitro af-
finity for both TPP and PTPP is reduced in these
mutant riboswitches and riboswitch-reporter gene ex-
pression is no longer regulated in response to extra-
cellular PT or thiamine. These results suggest that
PT is imported, phosphorylated to the biologically ac-
tive form PTPP, bound as PTPP to TPP riboswitches
with high affinity, and responsible for repressing ex-
pression of thiamine biosynthesis and import genes.
PT could then exert toxic effects by starving cells for
TPP, although other effects of PT on proteins might
also occur. PT resistance can be attained by mutating
TPP riboswitches to abolish ligand binding and con-
verting expression of the TPP-related genes to consti-
tutively high levels. Patterns of PT resistance can both
help further define thiamine metabolic pathways in
bacteria and also guide future drug development.
Our findings provide validation that TPP ribo-
switches are antimicrobial drug targets. This indicates
that antimicrobial compounds known for decades
function at least in part by a riboswitch-related mech-
anism. This also suggests a general antimicrobial drugdevelopment approach of generating analogs of ribo-
switch ligands that bind to riboswitches and disrupt
regulation of key metabolic pathways. Riboswitches
are attractive as targets for new antimicrobial drugs.
Riboswitches naturally evolved to bind ‘‘drug-like’’
molecules as small as 100 Da, and it is expected that
this natural binding ability will offer extensive oppor-
tunities for generating and screening small molecule
riboswitch inhibitors. Also, riboswitches control gene
expression associated with the levels of coenzymes
and other critical metabolites whose proper regulation
is expected to be essential for optimal growth.
Experimental Procedures
RNA Preparation and In-Line Probing
Chemicals and oligonucleotides were purchased and prepared as
reported previously [6]. RNA was transcribed in vitro from synthetic
DNA templates by T7 RNA polymerase. RNAs were prepared and la-
beled at the 50 end with 32P as described previously [58]. For in-line
probing, RNA was incubated forw40 hr at 25ºC in 20 mM MgCl2, 100
mM KCl, 50 mM Tris$HCl (pH 8.3) at 25ºC in the absence or presence
of various concentrations of thiamine, TPP, PT, or PTPP. Under
these conditions, spontaneous RNA breakdown due to positioning
effects is high enough to be measured accurately and reproducibly
but slow enough to limit degradation to one or a few events per RNA
molecule. RNAs are separated by denaturing PAGE on high-resolu-
tion gels.
PTPP Synthesis
Pyrithiamine pyrophosphate was prepared in the same manner as
hydroxyethylthiamine pyrophosphate syntheses reported previ-
ously [59, 60]. Pyrithiamine hydrobromide (fw 420.1) and phosphoric
acid crystal (99.999+%) were obtained from Sigma Aldrich (Mil-
waukee, WI). Crystalline phosphoric acid (400 mg, 4.08 mmol) was
heated over flame in a bottle with a loosely fitted aluminum foil cover.
The crystals liquefied, bubbled slightly, and then turned cloudy. This
liquid was cooled to room temperature. Pyrithiamine hydrobromide
(7.5 mg, 17.9 mmol) was added to the bottle along with a stir bar (3–5
mm). The bottle was covered loosely with aluminum foil and heated
in an oil bath at 105ºC–110ºC with gentle stirring for 15 min. This mix-
ture was cooled to room temperature. To quench the reaction (w2 ml
of 2.04 M phosphoric acid and 8.9 mM pyrithiamine derivatives),
1.6 ml of D2O was added. The bottle was tightly capped and the mix-
ture vortexed to dissolve the contents in D2O (white solid remained
undissolved). The clear solution was transferred to polyethylene
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1333tubes. After centrifugation, 0.8 ml of the uppermost solution was
transferred to an NMR sample tube and analyzed by 1H NMR and
31P NMR on Bruker (Fa¨llanden, Switzerland) 400 MHz or 500 MHz
NMR spectrometers. The proton NMR spectrum (internal reference:
D2O with 2.04 M phosphoric acid) was almost identical to that of
pyrithiamine except for protons close to phosphate ester: pyrithi-
amine (14.8 mM in D2O with 2.04 M phosphoric acid) d 3.00 (2H, t,
J = 6.20 Hz), d 2.24 (2H, t, J = 6.40 Hz); pyrithiamine mono-, di-, tri-
phosphate (14.8 mM in D2O with 2.04 M phosphoric acid) d 3.51
(2H, b), d 2.53 (2H, b). The proton-decoupled phosphorus NMR
spectrum showed three peaks (chemical shifts relative to 2.04 M
phosphoric acid) d –0.55 (monophosphate), d –11.4 (pyrophosphate),
d –24.5 (triphosphate). The conversion of the reaction determined by
proton NMR was >98% and the ratio of the phosphate esters deter-
mined by phosphorus NMR was <1% monophosphate, 85% pyro-
phosphate, and 15% triphosphate. This 7.57 mM pyrithiamine pyro-
phosphate solution (85% of 8.9 mM) contained no detectable side
products by NMR and could be used for the biological experiments
simply after dilution with buffer to adjust pH. In addition, PTPP was
prepared for related experiments and purified by reverse-phase
HPLC. A B. subtilis TPP riboswitch tested with the purified PTPP
was found to have approximately the same dissociation constant
(6 2-fold) with the purified PTPP as with PTPP prior to HPLC separa-
tion (data not shown).
Quantitation of Apparent Dissociation Constants
In-line probing gels were used to determine apparent KD values for
both the wild-type and mutant RNA sequences. Apparent KD values
were determined by quantitating (ImageQuaNT; GE Healthcare/
Amersham Biosciences AB, Piscataway, NJ) the amount of RNA
degradation for a given nucleotide position over a range of ligand
concentrations. The amount of degradation was normalized from
0 (no change in RNA degradation with and without ligand) to 1 (max-
imum change in degradation with and without ligand) for each site.
The apparent KD was determined by visual inspection of the plot of
normalized degradation (fraction cleaved) vs. ligand concentration
as demonstrated previously [6].
Construction of TPP Riboswitch-lacZ Fusions
Fusion of the tenA riboswitch with a lacZ reporter gene was used to
assess the expression inB. subtilis using methods similar to that de-
scribed previously [28]. The tenA DNA region comprising nucleoti-
des 2261 to +11 with respect to the translation start site was PCR
amplified as an EcoRI and BamHI fragment from the PT-resistant
strain 1A481 (Bacillus Genetic Stock Center, The Ohio State Univer-
sity, deposited by A. Gelizze) This sequence carries the point muta-
tion G-94 to A on the riboswitch, relative to the translation start site.
The PCR-amplified DNA was cloned into the pDG1661 reporter vec-
tor lacking an independent translation start site. A wild-type variant
of this construct was generated by oligonucleotide-directed muta-
genesis using wild-type primers. Constructs were integrated in the
amyE locus in strain 1A40 and confirmed as described [32]. The
E. coli thiC-lacZ fusion was constructed previously [6].
Thiamine Repression of b-Galactosidase Assays
Cells were grown as described [28] in defined medium under routine
conditions to an A600 of 0.2, at which time cells were split into three
aliquots in defined medium with and without supplements as noted.
Cultures were incubated for an additional 3 hr before performing the
b-galactosidase assay, similar to that of Miller [61].
Evolution of PT-Resistant Mutants
Resistant mutants were acquired with a method similar to a pub-
lished report [44]. A fresh overnight culture was diluted 1/100 in min-
imal medium with and without 100 mM PT. For E. coli, these cultures
were grown at 37ºC protected from light without shaking. B. subtilis
cultures were grown at 37ºC protected from light with shaking. When
PT-containing cultures were saturated, 10 ml was used to inoculate 1
ml each with minimal medium with and without 100 mM PT. Passages
were continued in this way until the culture with PT became satu-
rated in approximately the same time as those without PT (five pas-
sages).Sequencing
The 50-UTR of the thiC operon from E. coli strain PT-R1 was se-
quenced with primers EcThiC1 and EcThiC2 to amplify 2258 to
+10 relative to the translation start site. Twenty-four additional PT-
resistant E. coli clones were sequenced with these primers as
well. Twenty-three reactions gave readable sequences. The 16 PT-
resistant E. coli clones that did not have mutations in the thiC TPP
riboswitch were then sequenced in the 50-UTR of both the tbpA and
thiM operons. Sequencing of tbpA 50-UTR was done with primers
EcTbpA1 and EcTbpA2 (2226 to 21, relative to translation start),
sequencing of thiM 50-UTR with primers EcThiM1 and EcThiM2
(2172 to +2).
EcThiC1: 50-TAAGCGAATTCTGCTGGTGCTTGACG-30
EcThiC2: 50-CGCGTAGATCTCGGCGGGTCAGTTTTG-30
EcTbpA1: 50-GGGAATTCGCAACGCAGTATGCGCGGCCTG-30
EcTbpA2: 50-GACGGGATCCCCCAGCAGGGGCAGACATTTTTT
TAACAC-30
EcThiM1: 50-CTGCCGGAATTCCTCGTTTACAACGCGTG-30
EcThiM2: 50-TTGCGCTGGATCCAGCAGGTCGACTTGC-30
Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.chembiol.com/cgi/
content/full/12/12/1325/DC1/.
Acknowledgments
R.R.B. is cofounder of a biotechnology company, BioRelix, that is
pursuing licensing of intellectual property related to riboswitches.
We thank Dr. Jinsoo Lim for purification of PTPP. This work was sup-
ported by grants from the Defense Advanced Research Projects
Agency, National Institutes of Health, and the David and Lucile Pack-
ard Foundation. We thank members of the Breaker laboratory for
helpful discussions.
Received: September 1, 2005
Revised: October 4, 2005
Accepted: October 5, 2005
Published: December 16, 2005
References
1. Brantl, S. (2004). Bacterial gene regulation: from transcription at-
tenuation to riboswitches and ribozymes. Trends Microbiol. 12,
473–475.
2. Nudler, E., and Mironov, A.S. (2004). The riboswitch control of
bacterial metabolism. Trends Biochem. Sci. 29, 11–17.
3. Tucker, B.J., and Breaker, R.R. (2005). Riboswitches as versatile
gene control elements. Curr. Opin. Struct. Biol. 15, 342–348.
4. Barrick, J.E., Corbino, K.A., Winkler, W.C., Nahvi, A., Mandal, M.,
Collins, J., Lee, M., Roth, A., Sudarsan, N., Jona, I., et al. (2004).
New RNA motifs suggest an expanded scope for riboswitches
in bacterial genetic control. Proc. Natl. Acad. Sci. USA 101,
6421–6426.
5. Mandal, M., and Breaker, R.R. (2004). Adenine riboswitches and
gene activation by disruption of a transcription terminator. Nat.
Struct. Mol. Biol. 11, 29–35.
6. Winkler, W., Nahvi, A., and Breaker, R.R. (2002). Thiamine deriv-
atives bind messenger RNAs directly to regulate bacterial gene
expression. Nature 419, 952–956.
7. Winkler, W.C., Nahvi, A., Sudarsan, N., Barrick, J.E., and
Breaker, R.R. (2003). An mRNA structure that controls gene ex-
pression by binding S-adenosylmethionine. Nat. Struct. Biol. 10,
701–707.
8. Goodwin, T.W. (1963). The Biosynthesis of Vitamins and Related
Compounds (New York: Academic Press).
9. Sebrell, W.H., and Harris, R.S., eds. (1972). The Vitamins; Chem-
istry, Physiology, Pathology, Methods, Second Edition (New
York: Academic Press).
10. Tracy, A.H., and Elderfield, R.C. (1941). Studies in the pyridine
series. II. Synthesis of 2-methyl-3-(b-hydroxyethyl)pyridine and
Chemistry & Biology
1334of the pyridine analog of thiamine (vitamin B-1). J. Org. Chem. 6,
54–62.
11. Robbins, W.J. (1941). The pyridine analog of thiamin and the
growth of fungi. Proc. Natl. Acad. Sci. USA 27, 419–422.
12. Woolley, D.W., and White, A.G.C. (1943). Selective reversible
inhibition of microbial growth with pyrithiamine. J. Exp. Med.
78, 489–497.
13. Woolley, D.W., and White, A.G.C. (1943). Production of thiamine
deficiency disease by the feeding of a pyridine analogue of thia-
mine. J. Biol. Chem. 149, 285–289.
14. Koedam, J.C., Steyn-Parve, E.P., and Van Rheenen, D.L. (1956).
Thiamine deficiency after feeding pyrithiamine. Biochim. Bio-
phys. Acta 19, 181–182.
15. Iwashima, A., Wakabayashi, Y., and Nose, Y. (1976). Formation
of pyrithiamine pyrophosphate in brain tissue. J. Biochem.
(Tokyo) 79, 845–847.
16. Elnageh, K.M., and Zia-ur-Rahman, N.A. (2001). Simultaneous
separation and estimation of pyrithiamin and thiamin phosphate
esters in tissue of pyrithiamin treated rats. Int. J. Agric. Biol. 3,
178–180.
17. Woolley, D.W. (1951). An enzymatic study of the mode of action
of pyrithiamine (neopyrithiamine). J. Biol. Chem. 191, 43–54.
18. Iwashima, A., Wakabayashi, Y., and Nose, Y. (1975). Thiamine
transport mutants of Saccharomyces cerevisiae. Biochim. Bio-
phys. Acta 413, 243–247.
19. Heinrich, P.C., Janser, P., Wiss, O., and Steffen, H. (1972). Stud-
ies on the reconstitution of apotransketolase with thiamine pyro-
phosphate and analogs of the coenzyme. Eur. J. Biochem. 30,
533–541.
20. Wittorf, J.H., and Gubler, C.J. (1971). Coenzyme binding in yeast
pyruvate decarboxylase. Kinetic studies with thiamine diphos-
phate analogues. Eur. J. Biochem. 22, 544–550.
21. Rindi, G., Patrini, C., Nauti, A., Bellazzi, R., and Magni, P. (2003).
Three thiamine analogues differently alter thiamine transport
and metabolism in nervous tissue: an in vivo kinetic study using
rats. Metab. Brain Dis. 18, 245–263.
22. Todd, K., and Butterworth, R.F. (1999). Mechanisms of selective
neuronal cell death due to thiamine deficiency. Ann. N Y Acad.
Sci. 893, 404–411.
23. Pitkin, S.R., and Savage, L.M. (2004). Age-related vulnerability to
diencephalic amnesia produced by thiamine deficiency: the role
of time of insult. Behav. Brain Res. 148, 93–105.
24. Pires, R.G., Pereira, S.R., Oliveira-Silva, I.F., Franco, G.C., and
Ribeiro, A.M. (2005). Cholinergic parameters and the retrieval
of learned and re-learned spatial information: a study using
a model of Wernicke-Korsakoff Syndrome. Behav. Brain Res.
162, 11–21.
25. Kubodera, T., Yamashita, N., and Nishimura, A. (2000). Pyrithi-
amine resistance gene (ptrA) of Aspergillus oryzae: cloning,
characterization and application as a dominant selectable
marker for transformation. Biosci. Biotechnol. Biochem. 64,
1416–1421.
26. Kawasaki, T., Sanemori, H., Egi, Y., Yoshida, S., and Yamada, K.
(1976). Biochemical studies on pyrithiamine-resistant mutants
of Escherichia coli K12. J. Biochem. (Tokyo) 79, 1035–1042.
27. Kubodera, T., Watanabe, M., Yoshiuchi, K., Yamashita, N., Nish-
imura, A., Nakai, S., Gomi, K., and Hanamoto, H. (2003). Thia-
mine-regulated gene expression of Aspergillus oryzae thiA
requires splicing of the intron containing a riboswitch-like do-
main in the 50-UTR. FEBS Lett. 555, 516–520.
28. Sudarsan, N., Wickiser, J.K., Nakamura, S., Ebert, M.S., and
Breaker, R.R. (2003). An mRNA structure in bacteria that
controls gene expression by binding lysine. Genes Dev. 17,
2688–2697.
29. Griffiths-Jones, S., Moxon, S., Marshall, M., Khanna, A., Eddy,
S.R., and Bateman, A. (2005). Rfam: annotating non-coding
RNAs in complete genomes. Nucleic Acids Res. 33, D121–D124.
30. Griffiths-Jones, S., Bateman, A., Marshall, M., Khanna, A., and
Eddy, S.R. (2003). Rfam: an RNA family database. Nucleic Acids
Res. 31, 439–441.
31. Miranda-Rios, J., Navarro, M., and Soberon, M. (2001). A con-
served RNA structure (thi box) is involved in regulation of thiamin
biosynthetic gene expression in bacteria. Proc. Natl. Acad. Sci.
USA 98, 9736–9741.32. Mandal, M., Boese, B., Barrick, J.E., Winkler, W.C., and Breaker,
R.R. (2003). Riboswitches control fundamental biochemical
pathways in Bacillus subtilis and other bacteria. Cell 113,
577–586.
33. Mironov, A.S., Gusarov, I., Rafikov, R., Lopez, L.E., Shatalin, K.,
Kreneva, R.A., Perumov, D.A., and Nudler, E. (2002). Sensing
small molecules by nascent RNA: a mechanism to control tran-
scription in bacteria. Cell 111, 747–756.
34. Begley, T.P., Downs, D.M., Ealick, S.E., McLafferty, F.W., Van
Loon, A.P., Taylor, S., Campobasso, N., Chiu, H.-J., Kinsland,
C., Reddick, J.J., and Xi, J. (1999). Thiamin biosynthesis in
prokaryotes. Arch. Microbiol. 171, 293–300.
35. Settembre, E., Begley, T.P., and Ealick, S.E. (2003). Structural
biology of enzymes of the thiamin biosynthesis pathway. Curr.
Opin. Struct. Biol. 13, 739–747.
36. Lawhorn, B.G., Mehl, R.A., and Begley, T.P. (2004). Biosynthesis
of the thiamin pyrimidine: the reconstitution of a remarkable
rearrangement reaction. Org. Biomol. Chem. 2, 2538–2546.
37. Park, J.H., Dorrestein, P.C., Zhai, H., Kinsland, C., McLafferty,
F.W., and Begley, T.P. (2003). Biosynthesis of the thiazole moi-
ety of thiamin pyrophosphate (vitamin B1). Biochemistry 42,
12430–12438.
38. Leonardi, R., and Roach, P.L. (2004). Thiamine biosynthesis in
Escherichia coli: in vitro reconstitution of the thiazole synthase
activity. J. Biol. Chem. 279, 17054–17062.
39. Rodionov, D.A., Vitreschak, A.G., Mironov, A.A., and Gelfand,
M.S. (2002). Comparative genomics of thiamin biosynthesis in
procaryotes. New genes and regulatory mechanisms. J. Biol.
Chem. 277, 48949–48959.
40. Winkler, W.C., and Breaker, R.R. (2003). Genetic control by me-
tabolite-binding riboswitches. Chembiochem 4, 1024–1032.
41. Soukup, G.A., and Breaker, R.R. (1999). Relationship between
internucleotide linkage geometry and the stability of RNA. RNA
5, 1308–1325.
42. Soukup, G.A., DeRose, E.C., Koizumi, M., and Breaker, R.R.
(2001). Generating new ligand-binding RNAs by affinity matura-
tion and disintegration of allosteric ribozymes. RNA 7, 524–536.
43. Nahvi, A., Sudarsan, N., Ebert, M.S., Zou, X., Brown, K.L., and
Breaker, R.R. (2002). Genetic control by a metabolite binding
mRNA. Chem. Biol. 9, 1043–1049.
44. Kawasaki, T., and Nose, Y. (1969). Thiamine regulatory mutants
in Escherichia coli. J. Biochem. (Tokyo) 65, 417–425.
45. Kubodera, T., Yamashita, N., and Nishimura, A. (2002). Transfor-
mation of Aspergillus sp and Trichoderma reesei using the pyr-
ithiamine resistance gene (ptrA) of Aspergillus oryzae. Biosci.
Biotechnol. Biochem. 66, 404–406.
46. Sudarsan, N., Barrick, J.E., and Breaker, R.R. (2003). Metabolite-
binding RNA domains are present in the genes of eukaryotes.
RNA 9, 644–647.
47. Klier, A., Msadek, T., and Rapoport, G. (1992). Positive regula-
tion in the gram-positive bacterium: Bacillus subtilis. Annu.
Rev. Microbiol. 46, 429–459.
48. Toms, A.V., Haas, A.L., Park, J.H., Begley, T.P., and Ealick, S.E.
(2005). Structural characterization of the regulatory proteins
TenA and TenI from Bacillus subtilis and identification of TenA
as a thiaminase II. Biochemistry 44, 2319–2329.
49. Haas, A.L., Laun, N.P., and Begley, T.P. (2005). Thi20, a remark-
able enzyme from Saccharomyces cerevisiae with dual thiamin
biosynthetic and degradation activities. Bioorg. Chem. 33,
338–344.
50. Itou, H., Yao, M., Watanabe, N., and Tanaka, I. (2004). Structure
analysis of PH1161 protein, a transcriptional activator TenA
homologue from the hyperthermophilic archaeon Pyrococcus
horikoshii. Acta Crystallogr. D Biol. Crystallogr. 60, 1094–1100.
51. Benach, J., Edstrom, W.C., Lee, I., Das, K., Cooper, B., Xiao, R.,
Liu, J., Rost, B., Acton, T.B., Montelione, G.T., and Hunt, J.F.
(2005). The 2.35 A˚ structure of the TenA homolog from Pyrococ-
cus furiosus supports an enzymatic function in thiamine metab-
olism. Acta Crystallogr. D Biol. Crystallogr. 61, 589–598.
52. Murata, K. (1965). Thiaminase. In Review of Japanese Literature
on Beriberi and Thiamine, N. Shimazono, and E. Katsura, eds.
(Tokyo: Igaku Shoin), pp. 220–254.
53. Murata, K. (1982). Actions of two types of thiaminase on thiamin
and its analogues. Ann. N Y Acad. Sci. 378, 146–156.
Riboswitches as Drug Targets
133554. Costello, C.A., Kelleher, N.L., Abe, M., McLafferty, F.W., and
Begley, T.P. (1996). Mechanistic studies on thiaminase. I. Over-
expression and identification of the active site nucleophile.
J. Biol. Chem. 271, 3445–3452.
55. Shimazono, N., and Katsura, E., eds. (1965). Review of Japanese
Literature on Beriberi and Thiamine (Tokyo: Igaku Shoin).
56. Rogers, E.F. (1982). General discussion of antithiamin com-
pounds and thiamin antagonists. Ann. N Y Acad. Sci. 378,
157–160.
57. Morett, E., Korbel, J.O., Rajan, E., Saab-Rincon, G., Olvera, L.,
Olvera, M., Schmidt, S., Snel, B., and Bork, P. (2003). Systematic
discovery of analogous enzymes in thiamin biosynthesis. Nat.
Biotechnol. 21, 790–795.
58. Seetharaman, S., Zivarts, M., Sudarsan, N., and Breaker, R.R.
(2001). Immobilized RNA switches for the analysis of complex
chemical and biological mixtures. Nat. Biotechnol. 19, 336–341.
59. Kluger, R., Stergiopoulos, V., Gish, G., and Karimian, K. (1985).
Chiral intermediates in thiamin catalysis. Resolution and pyro-
phosphorylation of hydroxyethylthiamin. Bioorg. Chem. 13,
227–234.
60. Bearne, S.L., Gish, G., Karimian, K., and Kluger, R. (1989). Direct
selective pyrophosphorylation of the primary hydroxyl group in
(hydroxyethyl)thiamin by modified phosphoaric acid-cresol sol-
utions and evaluation of extension of the method to nucleosides.
Bioorg. Chem. 17, 224–230.
61. Miller, J.H. (1992). A Short Course in Bacterial Genetics (Cold
Spring Harbor, NY: Cold Spring Harbor Laboratory Press).
62. Mathews, D.H., Sabina, J., Zuker, M., and Turner, D.H. (1999).
Expanded sequence dependence of thermodynamic parame-
ters improves prediction of RNA secondary structure. J. Mol.
Biol. 288, 911–940.
63. Zuker, M. (2003). Mfold web server for nucleic acid folding and
hybridization prediction. Nucleic Acids Res. 31, 3406–3415.
